Colestipol Hydrochloride
Who holds supplier records for Colestipol Hydrochloride? 6 organisations hold a current record for Colestipol Hydrochloride: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (4), Taiwan (1) and United States (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records
Cite as: PharmaTek, “Colestipol Hydrochloride: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/colestipol-hydrochloride
Reading the evidence
- 6 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
4 of the 6 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (6)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Colestipol Hydrochloride. Country is the organisation's recorded country, not necessarily the manufacturing site.
- Formosa Laboratories, Inc.Taiwan Company GMP cert on recordActive DMF 17651 · latest filing Sept 2004
- RAKS PHARMA PVT LTDIndiaActive DMF 38026 · latest filing Feb 2023
- RISING PHARMA HOLDINGS INCUnited StatesActive DMF 33542 · latest filing Feb 2019
- SOLARA ACTIVE PHARMA SCIENCES LTDIndia Company GMP cert on recordActive DMF 33423 · latest filing Dec 2018
- Sun Pharmaceutical Industries LimitedIndia Company GMP cert on recordActive DMF 39413 · latest filing Nov 2024
- Zydus Lifesciences LimitedIndia Company GMP cert on recordActive DMF 33460 · latest filing Apr 2019
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Overview
Colestipol Hydrochloride is a non-absorbable polymeric compound used as a bile acid sequestrant for the treatment of hypercholesterolemia and other related conditions. It binds with bile acids in the intestine to form a complex that is excreted, thereby reducing serum cholesterol levels.
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Bile Acid Sequestrant
- Mechanism of action
- Bile-acid Binding Activity
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Colestipol Hydrochloride?
6 organisations hold an active US FDA Type II Drug Master File or a CEP for Colestipol Hydrochloride: Formosa Laboratories, Inc. (Taiwan), RAKS PHARMA PVT LTD (India), RISING PHARMA HOLDINGS INC (United States), SOLARA ACTIVE PHARMA SCIENCES LTD (India), Sun Pharmaceutical Industries Limited (India) and Zydus Lifesciences Limited (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Colestipol Hydrochloride Drug Master Files are active?
Formosa Laboratories, Inc. (DMF 17651), RAKS PHARMA PVT LTD (DMF 38026), RISING PHARMA HOLDINGS INC (DMF 33542), SOLARA ACTIVE PHARMA SCIENCES LTD (DMF 33423), Sun Pharmaceutical Industries Limited (DMF 39413) and Zydus Lifesciences Limited (DMF 33460). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
How do I qualify a Colestipol Hydrochloride supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Colestipol Hydrochloride?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.